Collective gain; individual pain

4Q Stock Wrap-Up

Collective gain; individual pain

Going into the fourth quarter, biotech industry watchers were split into two camps about how the year would end. One group felt that the lackluster performance in the middle six months would persist, while the other camp argued that depressed valuations and the slowdown in financing activity meant that investors could outstrip the supply of paper, thus positioning the sector for

Read the full 661 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers